AstraZeneca Pharma India Limited announced plans to launch Palivizumab (Synagis) in India this October. The company’s stocks were trading at ₹6,730, up by ₹13.75 (0.20 per cent) as of 10.23 ...

Hedge-fund powerhouse Two Sigma is likely to pay as much as $100 million to settle a Securities and Exchange Commission investigation into a trading scandal at the firm. The New York firm would ...

In spite of a significant reduction in the administration rate of palivizumab between the pre-2014 guideline and post-2014 guideline period, we did not find a significant increase in the RSV ...

That medicine - palivizumab was previously funded for at-risk babies using money ring-fenced for the Covid-19 response, and was shown to cut hospitalisations. But that funding ended in October 2023, ...

That means offering palivizumab – an older, more expensive antibody taken monthly during RSV season – to high-risk infants only, including babies born prematurely or with chronic lung and ...